Fundamental Data for MEDX

MEDAREX IN(NSDQ:MEDX)

Medarex Inc. is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. The company has developed a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse system for the creation of high-affinity human antibodies.Medarex creates and develops human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. (PRESS RELEASE)

# Employees: 488

Address: 707 State Road,Princeton,NJ,USA

Phone: 609-430-2880

Fax: 609-430-2850

Website: www.medarex.com

Email: information@medarex.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Irwin Lerner (Chmn.)

Christian S. Schade (Sr. V.P.; C.F.O. & Acctg. Off.)

Patricia M. Danzon (Dir.)

Robert C. Dinerstein (Dir.)

Howard H. Pien (Presi. C.E.O.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 6/30/2009

Next Earnings Date(Expected): 10/22/2009

Mean EPS (Next Qtr): ($0.33)

Mean EPS (Year): ($1.33)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 7

Shares Performance

Period	MEDX	Compare to S&P
YTD	186.38 %	151.77 %
4 Weeks	0.44 %	-3.87 %
12 Weeks	113.35 %	95.03 %

Shares Information

Analyst Coverage: Y

Avg Volume: 5304026

Shares Outstanding: 128M

Market Cap: $2.05B

52 Week High: $15.98

52 Week Low: $3.41

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 10/19/2000 MEDX split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: -6.25 %

EPS Growth in Last Year: 12.82 %

Sales Growth in Last Quarter: 79.95 %

Sales Growth in Last Quarter: 95.79 %

Financials

Qtr Book Value: $10.13

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 33.860